MARKET

AZN

AZN

Astrazeneca Plc
NASDAQ
67.72
-1.23
-1.78%
After Hours: 67.69 -0.03 -0.04% 16:18 05/13 EDT
OPEN
68.42
PREV CLOSE
68.95
HIGH
68.44
LOW
67.39
VOLUME
4.72M
TURNOVER
--
52 WEEK HIGH
86.44
52 WEEK LOW
61.24
MARKET CAP
210.02B
P/E (TTM)
27.22
1D
5D
1M
3M
1Y
5Y
1D
Bernstein Remains a Buy on AstraZeneca (AZN)
TipRanks · 7h ago
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
NASDAQ · 7h ago
Medicare to publish drugs selected for third round of price negotiations by Feb. 1
Seeking Alpha · 8h ago
Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
TipRanks · 9h ago
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
Barchart · 10h ago
FIBROGEN INC - CASH RUNWAY EXTENDED INTO 2H 2027 UPON SALE CLOSURE
Reuters · 1d ago
JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
TipRanks · 1d ago
Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
TipRanks · 1d ago
More
About AZN
More
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Recently
Symbol
Price
%Change

Webull offers AstraZeneca PLC (ADR) stock information, including NASDAQ: AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.